5 Best Peptides for SIBO

What to Know Before Choosing a Peptide for SIBO

SIBO is a condition where bacteria overpopulate the small intestine, fermenting carbohydrates before absorption and triggering a cascade of downstream damage: a degraded intestinal lining, disrupted tight junctions that allow bacterial products to leak into circulation, and a chronic inflammatory state that can outlast the bacterial overgrowth itself. Standard treatment targets the bacteria directly, most commonly with the antibiotic rifaximin. Peptides come in at a different layer.

Every compound in this guide earned its place because people use it or are actively discussing using it for SIBO. That is the whole test for inclusion. One is a supplement with generally recognized as safe status available over the counter. Others require a physician prescription through a compounding pharmacy. One has genuine human clinical trial data, though not from SIBO-specific research. Another exists almost entirely in community protocols with no published human trial data at all. All of them belong, and each entry states the evidence honestly rather than using evidence strength as a reason to exclude anything.

The five entries are ordered by how prominently each compound appears in published research and real-world use for SIBO. That order is a spine for the list, not a verdict. Number one is not the best option for you. The right compound, or combination of compounds, depends on which part of the SIBO damage picture you are trying to address, what else you are taking, and where you are in your treatment timeline. That personalized decision is what the MyPeptidePal app is designed to work through with you.

One thing worth understanding before diving in: none of these peptides replace treatment for the bacterial overgrowth itself. They work alongside antimicrobial treatment, or during the recovery period after it, to accelerate healing and support the conditions that reduce recurrence. That context shapes how every entry below should be read.

1. BPC-157: For Repairing Mucosal Damage Throughout Treatment

BPC-157 is a synthetic pentadecapeptide, a chain of 15 amino acids, derived from a partial sequence of a compound found in human gastric juice. It is the most frequently discussed peptide in SIBO community protocols and functional medicine circles, which is why it leads this list.

Its relevance to SIBO comes down to what the condition actually does to the gut lining. Bacterial overgrowth and the toxins it produces damage the intestinal epithelium, the thin cellular barrier separating the contents of your small intestine from your bloodstream. BPC-157 has been studied in rodent models for its ability to promote healing of this mucosal layer through angiogenesis, the growth of new blood vessels into damaged tissue, and through anti-inflammatory pathways. In those animal studies it has shown measurable effects on ulcer repair and GI tissue regeneration, and it appears to support restoration of the barrier function that SIBO disrupts.

One practical reason BPC-157 is favored for gut applications is that it can be taken orally and acts directly on the GI tract without requiring injection. Most peptides degrade in the stomach before reaching the small intestine, but BPC-157 has shown stability via the oral route in animal research, making it a natural fit for a gut-based condition. Users in community protocols typically take it in oral capsule or sublingual troche form throughout a SIBO treatment course.

The honest assessment of the evidence: no human clinical trial has been published evaluating BPC-157 for SIBO or for intestinal repair in humans. All existing data comes from preclinical animal studies and mechanistic research. Community feedback is genuinely mixed. Some users report meaningful improvement in gut comfort and inflammation during and after treatment. Others find it reduces symptoms without addressing the bacterial load, which is exactly what its mechanism would predict. It is a repair and anti-inflammatory tool, not an antimicrobial, and its appropriate role is as a support compound alongside, not instead of, antibacterial treatment.

BPC-157 is not FDA-approved and carries the agency's designation as a compound with significant safety concerns. No human trials have established its long-term safety profile. It is available through compounding pharmacies with a physician prescription; sourcing through unregulated channels carries meaningful contamination and mislabeling risk.

2. Larazotide: For Restoring Tight Junction Integrity

Larazotide, developed under the clinical name larazotide acetate and the trial designation AT-1001, is a synthetic octapeptide specifically designed to target intestinal permeability. Of all the compounds in this guide, it has the most advanced human clinical history, having been studied in randomized controlled trials for celiac disease and irritable bowel syndrome, though not for SIBO specifically.

Its mechanism is worth understanding in concrete terms. The intestinal lining is not a solid wall. It is made up of individual cells held together by tight junction proteins that act like the caulking between tiles. When SIBO bacteria release endotoxins, they signal the opening of those junctions through a protein called zonulin, creating gaps that allow bacterial products and antigens to pass into the bloodstream. This is the intestinal hyperpermeability that many SIBO patients develop, often experienced as food sensitivities and systemic inflammatory symptoms that persist even after the bacterial overgrowth is reduced. Larazotide works by blocking zonulin directly, helping to close those gaps and restore barrier integrity.

In celiac disease and IBS trials, larazotide reduced intestinal permeability and improved symptom scores in participants. Those are not SIBO trials, but the mechanism is directly applicable because SIBO triggers the same tight junction disruption. Users in SIBO-focused communities frequently report meaningful relief from bloating, food reactions, and the systemic symptoms that suggest bacterial translocation when using larazotide during or after antimicrobial treatment. One recurring description from users is that it "closes the gaps between gut lining cells," which is an accurate plain-English summary of its action.

Larazotide does not kill bacteria. Its role is structural: keeping the barrier from leaking while the bacterial population is addressed by other means. The adverse event profile from celiac and IBS trials has been mild, giving it a better-characterized safety picture than most compounds in this guide. It is available through compounding pharmacies with a physician prescription.

3. KPV: For the Inflammatory Burden After Bacterial Exposure

KPV is a tripeptide, a chain of just three amino acids (lysine, proline, and valine), derived from the C-terminal end of alpha-melanocyte-stimulating hormone. Its small size is a practical advantage for gut applications: as a very short peptide, it can survive transit through the GI tract and enter intestinal epithelial cells directly, allowing it to act on inflammation from inside the cell rather than only at the surface.

Its primary action is on the NF-kB pathway, a master switch for inflammation that bacterial endotoxins strongly activate. When SIBO bacteria release toxins, NF-kB signaling drives production of inflammatory molecules including IL-6, TNF-alpha, and IL-1beta, compounds that sustain the chronic gut inflammation and pain that many SIBO patients live with long after bacterial counts have been reduced. KPV suppresses this pathway and the cytokines it produces, generating an anti-inflammatory effect that some descriptions compare in potency to corticosteroids, without the typical adverse effects of steroid drugs.

The evidence comes primarily from murine models of inflammatory bowel disease, where KPV has shown reductions in colitis severity and inflammatory marker levels. No human clinical trial has evaluated it for SIBO. Its use in this context is built on the recognized mechanistic overlap between the inflammatory pathways active in IBD and those triggered by SIBO, combined with experience from the functional medicine community where it is most often discussed as part of a combination approach alongside BPC-157.

That pairing, KPV alongside BPC-157, is common enough that the two are available together in a combination product targeting gut repair. The logic is straightforward: BPC-157 addresses structural mucosal damage while KPV addresses the inflammatory state that the bacterial toxins have left behind. KPV is not FDA-approved; it is a research compound available through compounding pharmacies under physician oversight.

4. LL-37: For Antimicrobial Support and Concurrent Fungal Overgrowth

LL-37 is a cathelicidin antimicrobial peptide, and it is the only compound in this guide with genuine direct antimicrobial activity. The human body produces it endogenously, primarily in neutrophils and intestinal epithelial cells, as part of the innate immune system's front-line response to microbial invasion. The therapeutic version is a synthetic replicate of this endogenous molecule.

What distinguishes LL-37 from the other compounds here is its mechanism at the level of the bacterial membrane. Rather than targeting a specific bacterial metabolic pathway the way antibiotics do, it disrupts bacterial cell membranes directly. That action is broad-spectrum, active against both gram-positive and gram-negative bacteria, and it extends to fungi as well. The antifungal activity is particularly relevant for SIBO cases where small intestinal fungal overgrowth (SIFO) coexists with the bacterial overgrowth, a concurrent condition that standard antibacterial protocols do not address.

The evidence base for LL-37 in this context is primarily in vitro. Laboratory studies have well-characterized its antimicrobial activity against a wide range of pathogens, and animal research has shown immune-modulating and gut barrier-protective effects. No human clinical trial has evaluated it specifically for SIBO. Its use in this context is anecdotal, appearing most often in community accounts of recurrent or treatment-resistant SIBO where practitioners added LL-37 as an adjunctive antimicrobial layer alongside standard protocols.

Because LL-37 is primarily administered by injection for systemic antimicrobial effects and has less established oral stability than BPC-157 or KPV, it tends to appear later in protocols rather than as a starting point. It is not FDA-approved for therapeutic use and is available through compounding pharmacies under physician supervision. Given that its primary mechanism involves immune activation, it warrants particular caution for anyone with autoimmune conditions.

5. Tributyrin: For Mucosal Fuel and Barrier Support After Treatment

Tributyrin occupies a distinct category in this guide. It is technically a lipid prodrug rather than a peptide, a triglyceride molecule where three butyrate groups are bound to a glycerol backbone. When gut lipases break it down in the intestinal lumen, it releases butyric acid, the short-chain fatty acid that serves as the primary fuel source for intestinal epithelial cells. It is included here because it shows up consistently in functional medicine SIBO protocols alongside the peptides above, and its mechanism addresses several of the same damage pathways.

Butyrate matters to the SIBO recovery picture in several ways. It is the primary energy source for the cells lining the intestinal wall, and a gut recovering from bacterial overgrowth is often depleted of the raw materials needed to rebuild that lining. Butyrate also upregulates the expression of tight junction proteins, including claudin, occludin, and ZO-1, directly addressing the structural barrier disruption that SIBO causes, which puts it in parallel territory with larazotide though via a different mechanism. It also suppresses NF-kB signaling, adding an anti-inflammatory dimension that overlaps with KPV's mechanism, and it supports goblet cell function, which maintains the mucus layer that normally keeps bacteria from colonizing too close to the epithelium.

Tributyrin's advantage over simpler butyrate salts like sodium butyrate is delivery. Free butyrate supplements tend to be absorbed in the stomach and upper intestine before reaching the areas most affected by SIBO. Because tributyrin must be hydrolyzed by lipases, it releases butyrate further down the tract, closer to the relevant tissue.

The human evidence draws from supplement and IBD research rather than SIBO-specific trials. Animal data supports its gut-protective effects. No human clinical trial has evaluated tributyrin specifically for SIBO. Its status as a generally recognized as safe food additive means it is available over the counter as a dietary supplement without a prescription, making it the most accessible compound in this guide and the one with the lowest regulatory threshold. It is most commonly discussed in functional medicine SIBO protocols as a post-antimicrobial support tool during the recovery and barrier-restoration phase, often stacked with BPC-157 and larazotide.

How These Peptides Compare

Frequently Asked Questions

Do any of these peptides actually kill SIBO bacteria?

Only LL-37 has direct antimicrobial properties, and even that is not a primary eradication tool in the way rifaximin or herbal antimicrobials are. BPC-157, KPV, Larazotide, and Tributyrin work on the downstream damage that SIBO causes, repairing the gut lining, reducing inflammation, and restoring barrier integrity, rather than reducing bacterial load. Community consensus is consistent on this point: these compounds work best alongside antimicrobial treatment, not as replacements for it.

Are any of these compounds FDA-approved?

Larazotide has the most advanced investigational history of the group, having been studied in human clinical trials for celiac disease and IBS, but it is not FDA-approved. BPC-157, KPV, and LL-37 are research compounds available through compounding pharmacies under physician supervision, with no approved indication. Tributyrin is the outlier: it holds generally recognized as safe status as a food additive and is available over the counter without a prescription, though it is not approved as a drug treatment for SIBO.

Can these be taken orally, or do they require injection?

BPC-157, KPV, Larazotide, and Tributyrin are all commonly taken orally and act directly on GI tissue, which makes the oral route particularly well suited to a condition that lives in the gut. LL-37 is typically administered by injection for systemic antimicrobial effects, and its stability via the oral route is less established than the others. One reason BPC-157 has become the most discussed peptide for gut conditions is precisely that it appears orally stable in animal research, removing the injection barrier for people managing a GI condition.

How does SIBO damage the gut lining, and why does that matter for choosing a peptide?

SIBO bacteria ferment carbohydrates and release toxins that erode the intestinal epithelium and loosen the tight junctions holding it together, creating intestinal hyperpermeability where bacterial products can reach the bloodstream and trigger systemic inflammation. Understanding which part of that picture is most prominent helps clarify which compound addresses it. Larazotide is specific to the tight junction problem. BPC-157 and Tributyrin target the epithelial repair side. KPV addresses the downstream inflammatory cascade. LL-37 adds an antimicrobial layer. Most people dealing with SIBO-related damage are contending with more than one of these simultaneously, which explains why combination approaches are common in community protocols.

How long before these compounds show results in a SIBO recovery protocol?

No clinical timeline has been established for any of these compounds in SIBO specifically. In community protocols, users report noticing changes in gut comfort, bloating, and food tolerance over weeks rather than days, consistent with the pace of tissue repair rather than an acute antimicrobial effect. Results vary considerably depending on the severity of the underlying damage, what antimicrobial treatment is being used alongside, and individual factors. These are support tools in what is often a multi-month recovery process, not fast-acting symptom relievers.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for SIBO in one place.